{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:59Z","timestamp":1786988039544,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116807","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:02:10Z","timestamp":1779145330000},"page":"116807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9008-8573","authenticated-orcid":false,"given":"Zofia","family":"Piotrowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-633X","authenticated-orcid":false,"given":"Adrianus J.","family":"de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena A.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2000-7472","authenticated-orcid":false,"given":"Kazumi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5418-2545","authenticated-orcid":false,"given":"Paul.E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-5159","authenticated-orcid":false,"given":"Kwan Ho","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6349-0332","authenticated-orcid":false,"given":"Jonathan M.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116807_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116807_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116807_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116807_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116807_bib5","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non\u2013small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116807_bib6","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116807_bib7","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1200\/JCO-25-02822","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, 2026.3.0","volume":"44","author":"Puri","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116807_bib8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116807_bib9","unstructured":"US Food & Drug Administration (FDA). FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer\u3009; 2025 [accessed 09 December 2025]."},{"key":"10.1016\/j.ejca.2026.116807_bib11","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.annonc.2025.06.007","article-title":"Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline","author":"Hendriks","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116807_bib13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/cancers17030459","article-title":"Optimizing osimertinib for NSCLC: targeting resistance and exploring combination therapeutics","volume":"17","author":"Liao","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116807_bib14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ijc.29825","article-title":"The distribution of BRAF gene fusions in solid tumors and response to targeted therapy","volume":"138","author":"Ross","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.116807_bib15","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.jtho.2019.05.046","article-title":"Response to the combination of osimertinib and trametinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF fusion","volume":"14","author":"Dagogo-Jack","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116807_bib16","first-page":"1019","article-title":"EGFR\/BRAF\/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF(V600E) mutation: a case report and review of literature","volume":"4","author":"Zeng","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ejca.2026.116807_bib17","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.21037\/tlcr-24-358","article-title":"Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients","volume":"13","author":"Weng","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2026.116807_bib18","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116807_bib19","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","article-title":"The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer","volume":"16","author":"Banerji","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116807_bib21","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","article-title":"Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models","volume":"75","author":"Eberlein","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116807_bib22","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1158\/1078-0432.CCR-21-4329","article-title":"Osimertinib plus selumetinib in EGFR-mutated non-small cell lung cancer after progression on EGFR-TKIs: A phase Ib, open-label, multicenter trial (TATTON Part B)","author":"Yang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116807_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116807_bib24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cllc.2021.06.006","article-title":"Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced\/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD)","volume":"6","author":"Yu","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116807_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/pst.1746","article-title":"Decision-making in early clinical drug development","volume":"15","author":"Frewer","year":"2016","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ejca.2026.116807_bib26","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116807_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae312","article-title":"COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer","volume":"30","author":"Mehlman","year":"2025","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.ejca.2026.116807_bib28","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.21037\/tlcr-24-803","article-title":"EGFR inhibitors plus dabrafenib and trametinib in patients with EGFR-mutant lung cancer and resistance mediated by BRAF(V600E) mutation: a multi-center real-world experience in China","volume":"13","author":"Yang","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2026.116807_bib29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:55:17Z","timestamp":1781153717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":26,"alternative-id":["S0959804926005885"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116807","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116807"}}